T1	PROC 46 67	Estudios de extensión
T2	CHEM 96 105	Ibrutinib
#1	AnnotatorNotes T2	C3501358; ibrutinib; Organic Chemical · Pharmacologic Substance
T3	PROC 130 182	Estudio fase 3b multicéntrico, abierto, de extensión
T4	CHEM 211 220	Ibrutinib
#2	AnnotatorNotes T4	C3501358; ibrutinib; Organic Chemical · Pharmacologic Substance
T5	DISO 246 274	Leucemia linfocítica crónica
#3	AnnotatorNotes T5	C0023434; Chronic Lymphocytic Leukemia; Neoplastic Process
T6	DISO 277 316	linfoma linfocítico de células pequeñas
T7	ANAT 300 316	células pequeñas
T8	DISO 318 346	linfoma de células del manto
#4	AnnotatorNotes T8	C4721414; Mantle cell lymphoma; Neoplastic Process
T9	DISO 348 365	linfoma folicular
#5	AnnotatorNotes T9	C0024301; Lymphoma, Follicular; Neoplastic Process
T10	DISO 368 401	linfoma difuso de célula grande B
#6	AnnotatorNotes T10	C0079744; Diffuse Large B-Cell Lymphoma; Neoplastic Process
T11	ANAT 386 401	célula grande B
#7	AnnotatorNotes T11	C0004561; B-Lymphocytes; Cell
T12	PROC 500 514	ensayo clínico
#8	AnnotatorNotes T12	C0008976; Clinical Trials; Research Activity
T13	PROC 600 611	tratamiento
#9	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	CHEM 85 94	PCI-32765
#10	AnnotatorNotes T14	C2830052; PCI 32765; Pharmacologic Substance
T15	PROC 695 721	tratamiento en monoterapia
T16	CHEM 726 735	PCI-32765
#11	AnnotatorNotes T16	C2830052; PCI 32765; Pharmacologic Substance
T17	PROC 786 809	métodos anticonceptivos
#12	AnnotatorNotes T17	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T18	PROC 839 848	protocolo
#13	AnnotatorNotes T18	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T19	PROC 866 882	test de embarazo
#14	AnnotatorNotes T19	C0032976; Pregnancy Tests; Diagnostic Procedure
T20	ANAT 895 901	sangre
#15	AnnotatorNotes T20	C0005767; Blood; Body Substance
T21	PROC 969 984	anticoagulación
#16	AnnotatorNotes T21	C0150457; Anticoagulant therapy; Therapeutic or Preventive Procedure
T22	CHEM 616 625	PCI-32765
#17	AnnotatorNotes T22	C2830052; PCI 32765; Pharmacologic Substance
T23	PROC 1053 1064	tratamiento
#18	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	ANAT 356 365	folicular
T25	ANAT 255 266	linfocítica
#19	AnnotatorNotes T25	C0024264; Lymphocyte; Cell
T26	ANAT 285 296	linfocítico
#20	AnnotatorNotes T26	C0024264; Lymphocyte; Cell
T27	ANAT 329 336	células
#21	AnnotatorNotes T27	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T28	CHEM 519 528	PCI-32765
#22	AnnotatorNotes T28	C2830052; PCI 32765; Pharmacologic Substance
T29	ANAT 904 909	orina
#23	AnnotatorNotes T29	C0042036; Urine; Body Substance
T30	CHEM 989 998	warfarina
#24	AnnotatorNotes T30	C0043031; warfarin; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T31	CHEM 1001 1027	antagonistas de vitamina K
#25	AnnotatorNotes T31	C2267235; Vitamin K Antagonist; Pharmacologic Substance
T32	CHEM 1069 1120	inhibidores potentes del citocromo P450 (CYP) 3A4/5
T33	CHEM 200 209	PCI-32765
#26	AnnotatorNotes T33	C2830052; PCI 32765; Pharmacologic Substance
T34	Date 13 17	2012
T35	Date 68 81	a largo plazo
T36	Date 183 196	a largo plazo
T37	Duration 267 274	crónica
#27	AnnotatorNotes T37	C0205191; chronic; Temporal Concept
T38	LIVB 435 456	sujetos participantes
#28	AnnotatorNotes T38	C0681850; Study Subject; Group + C4554048; Study Participant; Population Group
T39	Date 469 480	actualmente
T40	Duration 580 596	al menos 6 meses
T41	Neg_cue 883 891	negativo
T44	LIVB 1236 1248	investigador
#29	AnnotatorNotes T44	C0035173; Research Personnel; Professional or Occupational Group
T49	PHYS 874 882	embarazo
#30	AnnotatorNotes T49	C0032961; Pregnancy; Organism Function
T42	LIVB 1424 1434	voluntario
#31	AnnotatorNotes T42	C0020155; Human Volunteers; Population Group
T43	LIVB 1265 1277	participante
#32	AnnotatorNotes T43	C4554048; Study Participant; Population Group
T45	LIVB 658 671	participantes
#33	AnnotatorNotes T45	C4554048; Study Participant; Population Group
A1	Assertion T49 Negated
#34	AnnotatorNotes T35	C0443252; Long-term; Temporal Concept
#35	AnnotatorNotes T36	C0443252; Long-term; Temporal Concept
#36	AnnotatorNotes T39	C0521116; Current (present time); Temporal Concept 
T46	Spec_cue 1250 1255	pueda
T47	Observation 1284 1304	riesgo significativo
A2	Assertion T47 Speculated
R1	Experiences Arg1:T43 Arg2:T47	
R2	Speculation Arg1:T46 Arg2:T47	
T48	Spec_cue 1306 1311	pueda
T50	Observation 1312 1346	afectar los resultados del estudio
A3	Assertion T50 Speculated
#37	AnnotatorNotes T50	C0521102; Interferes with; Functional Concept
T51	Spec_cue 1350 1355	pueda
T52	CONC 1356 1366	interferir
A4	Assertion T52 Speculated
#38	AnnotatorNotes T52	C0521102; Interferes with; Functional Concept
R3	Speculation Arg1:T51 Arg2:T52	
R4	Speculation Arg1:T48 Arg2:T50	
R5	Overlap Arg1:T1 Arg2:T35	
R6	Overlap Arg1:T3 Arg2:T36	
R7	Location_of Arg1:T25 Arg2:T5	
R8	Has_Duration_or_Interval Arg1:T5 Arg2:T37	
R9	Location_of Arg1:T26 Arg2:T6	
R10	Location_of Arg1:T27 Arg2:T8	
#39	AnnotatorNotes T7	C1518241; Malignant Small Cell; Cell (?) | C1514085; Neoplastic Small Cell; Cell (?)
R11	Location_of Arg1:T7 Arg2:T6	
R12	Location_of Arg1:T24 Arg2:T9	
T53	ANAT 341 346	manto
#40	AnnotatorNotes T53	C3846131; Mantle; Body Location or Region
R13	Location_of Arg1:T53 Arg2:T8	
#41	AnnotatorNotes T24	C1571705; Follicle; Body Part, Organ, or Organ Component
R14	Location_of Arg1:T11 Arg2:T10	
R15	Experiences Arg1:T38 Arg2:T28	
R16	Overlap Arg1:T28 Arg2:T39	
T54	Observation 500 514;546 556	ensayo clínico completado
#42	AnnotatorNotes T54	C2732579; Completion of clinical trial; Finding
R18	Overlap Arg1:T54 Arg2:T39	
R19	Has_Duration_or_Interval Arg1:T22 Arg2:T40	
R20	Used_for Arg1:T22 Arg2:T13	
R21	Experiences Arg1:T38 Arg2:T13	
R22	Experiences Arg1:T45 Arg2:T15	
R23	Used_for Arg1:T16 Arg2:T15	
#43	AnnotatorNotes T15	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T55	Quantifier_or_Qualifier 736 751	de forma activa
#44	AnnotatorNotes T55	C0679217; Active State; Idea or Concept
R24	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T55	
T56	Quantifier_or_Qualifier 810 819	efectivos
#45	AnnotatorNotes T56	C1280519; Effectiveness; Qualitative Concept
R25	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T56	
R26	Negation Arg1:T41 Arg2:T49	
R27	Location_of Arg1:T20 Arg2:T19	
R28	Location_of Arg1:T29 Arg2:T19	
T57	PROC 921 930	selección
#46	AnnotatorNotes T57	C0242802; Patient Selection; Research Activity
R29	Overlap Arg1:T19 Arg2:T57	
R30	Used_for Arg1:T30 Arg2:T21	
R31	Used_for Arg1:T31 Arg2:T21	
R32	Used_for Arg1:T32 Arg2:T23	
T58	Observation 1393 1419	participación en el ensayo
#47	AnnotatorNotes T58	C1278516; Patient participation status; Finding (?)
R34	Overlap Arg1:T47 Arg2:T58	
R35	Experiences Arg1:T42 Arg2:T47	
#48	AnnotatorNotes T6	C0855095; Small Lymphocytic Lymphoma; Neoplastic Process
#49	AnnotatorNotes T47	C4319571; High risk; Finding
A5	Experiencer T44 Other
A6	Experiencer T43 Patient
A7	Experiencer T42 Patient
A8	Experiencer T38 Patient
A9	Experiencer T45 Patient
T59	Result_or_Value 883 891	negativo
R17	Has_Result_or_Value Arg1:T19 Arg2:T59	
